{"nctId":"NCT00722371","briefTitle":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","startDateStruct":{"date":"2008-09-05","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":1615,"armGroups":[{"label":"Sitagliptin 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin phosphate","Drug: Matching placebo to pioglitazone","Drug: Metformin"]},{"label":"Pioglitazone 15 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Pioglitazone hydrochloride","Drug: Matching placebo to sitagliptin","Drug: Metformin"]},{"label":"Pioglitazone 30 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Pioglitazone hydrochloride","Drug: Matching placebo to sitagliptin","Drug: Metformin"]},{"label":"Pioglitazone 45 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Pioglitazone hydrochloride","Drug: Matching placebo to sitagliptin","Drug: Metformin"]},{"label":"Sitagliptin 100 mg/ Pioglitazone 15 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin phosphate","Drug: Pioglitazone hydrochloride","Drug: Metformin"]},{"label":"Sitagliptin 100 mg/ Pioglitazone 30 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin phosphate","Drug: Pioglitazone hydrochloride","Drug: Metformin"]},{"label":"Sitagliptin 100 mg/ Pioglitazone 45 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin phosphate","Drug: Pioglitazone hydrochloride","Drug: Metformin"]}],"interventions":[{"name":"Sitagliptin phosphate","otherNames":["Januvia","Tesavel","Xelevia","Ristaben"]},{"name":"Pioglitazone hydrochloride","otherNames":["Actos"]},{"name":"Matching placebo to sitagliptin","otherNames":[]},{"name":"Matching placebo to pioglitazone","otherNames":[]},{"name":"Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient is highly unlikely to conceive\n* Patient meets one of the 3 categories is naÃ¯ve to all antihyperglycemic agent (AHA) therapies, or is non-naÃ¯ve based upon the patient's current diet, medical regimen and screening A1c patient is currently not on AHA with a screening A1c \\>=7.5 % and =\\<11.0 % patient is currently on either metformin pr sulfonylurea monotherapy with a screening A1c \\>=7.0 % and =\\<9.0 %\n\nExclusion Criteria\n\n* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis or has C=peptide value of =\\<0.8 ng/mL\n* Patient has previously been treated with insulin, thiazolidinedione (TZD) (rosiglitazone or pioglitazone), any Dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin, vildagliptin, or alogliptin), exenatide or has previously been in a clinical study with any DPP-4 inhibitor or incretin mimetic\n* Patient is on a weight loss program and is not in the maintenance phase or has started a weight loss medication (e.g. orlistat or sibutramine) within the prior 8 weeks\n* Patient has undergone surgery within the prior 30 days or has major surgery planned during the study\n* Patient has a medical history of active liver disease including chronic active hepatitis B or C or symptomatic gallbladder disease including primary biliary cirrhosis\n* Patient has received treatment with an investigational product within 12 weeks prior to Visit 1","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1C (A1C) at Week 24","description":"A1C represents the percentage of glycosylated hemoglobin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.09","spread":null},{"groupId":"OG001","value":"-0.88","spread":null},{"groupId":"OG002","value":"-1.21","spread":null},{"groupId":"OG003","value":"-1.20","spread":null},{"groupId":"OG004","value":"-1.53","spread":null},{"groupId":"OG005","value":"-1.63","spread":null},{"groupId":"OG006","value":"-1.81","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.3","spread":null},{"groupId":"OG001","value":"-19.5","spread":null},{"groupId":"OG002","value":"-29.9","spread":null},{"groupId":"OG003","value":"-37.4","spread":null},{"groupId":"OG004","value":"-41.0","spread":null},{"groupId":"OG005","value":"-46.9","spread":null},{"groupId":"OG006","value":"-52.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 24","description":"PMG was measured using the Meal Tolerance Test (MTT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.1","spread":null},{"groupId":"OG001","value":"-30.6","spread":null},{"groupId":"OG002","value":"-52.5","spread":null},{"groupId":"OG003","value":"-66.6","spread":null},{"groupId":"OG004","value":"-69.2","spread":null},{"groupId":"OG005","value":"-85.5","spread":null},{"groupId":"OG006","value":"-93.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in A1C at Week 54","description":"A1C represents the percentage of glycosylated hemoglobin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":null},{"groupId":"OG001","value":"-0.74","spread":null},{"groupId":"OG002","value":"-1.16","spread":null},{"groupId":"OG003","value":"-1.23","spread":null},{"groupId":"OG004","value":"-1.45","spread":null},{"groupId":"OG005","value":"-1.49","spread":null},{"groupId":"OG006","value":"-1.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG at Week 54","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.1","spread":null},{"groupId":"OG001","value":"-10.5","spread":null},{"groupId":"OG002","value":"-24.0","spread":null},{"groupId":"OG003","value":"-33.3","spread":null},{"groupId":"OG004","value":"-33.9","spread":null},{"groupId":"OG005","value":"-37.1","spread":null},{"groupId":"OG006","value":"-47.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-Hour PMG at Week 54","description":"PMG was measured using the Meal Tolerance Test (MTT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.0","spread":null},{"groupId":"OG001","value":"-26.7","spread":null},{"groupId":"OG002","value":"-46.8","spread":null},{"groupId":"OG003","value":"-58.2","spread":null},{"groupId":"OG004","value":"-64.7","spread":null},{"groupId":"OG005","value":"-69.7","spread":null},{"groupId":"OG006","value":"-88.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":231},"commonTop":["Hypoglycaemia","Nasopharyngitis","Headache","Upper respiratory tract infection","Hypertension"]}}}